Immune Pharmaceuticals (IMNP) versus Apricus Biosciences (APRI) Head to Head Review

Immune Pharmaceuticals (NASDAQ: IMNP) and Apricus Biosciences (NASDAQ:APRI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Insider and Institutional Ownership

1.8% of Immune Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.4% of Apricus Biosciences shares are owned by institutional investors. 6.7% of Immune Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Apricus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Immune Pharmaceuticals and Apricus Biosciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immune Pharmaceuticals N/A N/A -$32.66 million ($4.20) -0.09
Apricus Biosciences $5.76 million 2.70 -$7.43 million ($0.93) -1.10

Apricus Biosciences has higher revenue and earnings than Immune Pharmaceuticals. Apricus Biosciences is trading at a lower price-to-earnings ratio than Immune Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Immune Pharmaceuticals has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Apricus Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Immune Pharmaceuticals and Apricus Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immune Pharmaceuticals 0 0 1 0 3.00
Apricus Biosciences 0 1 1 0 2.50

Immune Pharmaceuticals currently has a consensus target price of $3.00, indicating a potential upside of 717.22%. Apricus Biosciences has a consensus target price of $1.00, indicating a potential downside of 1.96%. Given Immune Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Immune Pharmaceuticals is more favorable than Apricus Biosciences.

Profitability

This table compares Immune Pharmaceuticals and Apricus Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immune Pharmaceuticals N/A -1,443.76% -117.17%
Apricus Biosciences N/A -527.09% -126.76%

Summary

Immune Pharmaceuticals beats Apricus Biosciences on 6 of the 11 factors compared between the two stocks.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

About Apricus Biosciences

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply